Q-omics provides the consensus-scored NPNT profile across patient tissues and cancer cell-line models. NPNT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NPNT is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NPNT RNA expression shows 18,608 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where NPNT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPNT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPNT survival associations across molecular data types. NPNT RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPNT RNA expression–survival associations across cancer types. High NPNT expression shows unfavorable associations in UVM, ACC, LGG and BLCA, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NPNT RNA expression.
This table summarizes NPNT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NPNT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPNT shows lower tumor expression in KIRC, LUAD, KIRP and LUSC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher NPNT RNA expression in tumor versus normal tissue (log2 FC = +2.737, t-test p < 0.001).
This table shows molecular features associated with NPNT in patient tissues and cancer cell lines. In patient samples, NPNT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPNT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
